Get Kiniksa Pharmaceuticals International alerts:View Our Latest Stock Analysis on Kiniksa Pharmaceuticals InternationalKiniksa Pharmaceuticals International Trading Up 0.8%Shares of NASDAQ KNSA traded up $0.60 during midday trading on Wednesday, reaching $80.05. Insider ActivityIn other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, May 1st. Key Headlines Impacting Kiniksa Pharmaceuticals InternationalHere are the key news stories impacting Kiniksa Pharmaceuticals International this week:Positive Sentiment: Citigroup raised its price target to $100 from $60 and upgraded KNSA to “buy.” Zacks KNSA Earnings ReportKiniksa Pharmaceuticals International Company Profile(Get Free Report)Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Featured ArticlesReceive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.